StockTipsArenaBeta

BUY Cipla Ltd. — Sharekhan Research

BUYCipla Ltd.

bySharekhan ResearchHorizon: NA (inferred 1 year)2 Sept 2025via Institutional / Brokerage Research

Entry₹1,569.2Inferred
Target₹1,754
Total upside +11.78% (call closed)
Stop lossNot given
At expiry₹1,412.82 Sept 2026, 3:30 pm
Expired-9.97%auction close
Follow Sharekhan Research for new calls(54% target hit, 510 closed calls)Get alertsWatch CIPLA for new buy/sell callsGet alertsSee 15 active Long-term calls on CIPLASee 85 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 2 Sept 2026
11 supporting18 neutral21 opposing
Supports the BUY call (11)

Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix

NewsCnbc-Tv18·1 Sept · today

(opens in new tab)

Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm

NewsCnbc-Tv18·1 Sept · yesterday

(opens in new tab)

Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets

NewsCnbc-Tv18·31 Aug · yesterday

(opens in new tab)

Cipla Ltd has signed an exclusive licensing agreement with SBP Group for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC.

BSE · Company Update·31 Aug · yesterday

(opens in new tab)

6 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·26 Aug · 1w ago

Neutral / worth noting (18)

US FDA classifies Cipla subsidiary’s New York facility inspection as ‘Voluntary Action Indicated’

NewsCnbc-Tv18·29 Aug · 4d ago

(opens in new tab)

Cipla Pharma License Cancellation: FDA Withdraws Order After HC Raps It For Going "Overboard"

NewsNdtv-Profit·29 Aug · 4d ago

(opens in new tab)

Cipla shares slip after USFDA observations; Citi says no earnings impact, target at ₹1,700

NewsCnbc-Tv18·26 Aug · 1w ago

(opens in new tab)

Nifty, Sensex open lower; TCS, Eternal gain, Cipla, Maruti slip

NewsHbl·25 Aug · 1w ago

(opens in new tab)

Nifty, Sensex open lower on Iran sanctions, tech selloff; TCS, Eternal gain while Cipla, Maruti slip

NewsHbl·25 Aug · 1w ago

(opens in new tab)
Weighs against the BUY call (21)

Cipla Pharma license cancellation: FDA withdraws order after Bombay HC raps it for going 'overboard'

NewsCnbc-Tv18·29 Aug · 3d ago

(opens in new tab)

FDA Crackdown: Cipla Arm Loses Pune Drug Sales Licence For Storage Deficiencies, Illegal Ads

NewsNdtv-Profit·28 Aug · 4d ago

(opens in new tab)

Cipla gets seven USFDA observations for Pithampur plant after follow-up inspection

NewsCnbc-Tv18·25 Aug · 1w ago

(opens in new tab)

3 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·24 Jul · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.